DuPont and Inbiose infant formula HMO gains EU approval

The ingredient 2’-Fucosyllactose (2’-FL) is to be marketed by DuPont under the brand name CARE4U, having already been approved for use in dietary supplements. DuPont have earmarked the HMO as a core ingredient in potential applications for the future that are related to digestion and immune health. “The substantial equivalence dossier for 2’-FL received EU Novel Food approval in December 2017,​” said Paul Tenning, DuPont’s regulatory affairs manager, EMEA. “We are excited to be able to bring this important new ingredient for infants and children into the European market.​” 2016 agreement ​ News of regulatory approval for 2’FL means the firms’ joint development and licensing agreement to produce and commercialise 2’-FL, agreed back in 2016 are on track. This agreement, which also looks to develop other fucosylated HMOs, combines Inbiose’s carbohydrate production platform with DuPont’s industrial-scale fermentation facilities. “After many years of research and investment, we are delighted to see the first of our range of human milk oligosaccharides becoming commercially available, thus addressing a major gap in the nutritional composition of infant formula,”​ said Professor Wim Soetaert, Inbiose’s executive chairman. “Thanks to our collaboration with DuPont, our first HMO is now commercialised, with many others to come.”​ Cost-effective HMO production​ HMOs are a group of unique oligosaccharides found in mother’s milk, wi...
Source: Nursing Comments - Category: Nursing Authors: Tags: Nutrition Source Type: blogs